Work

OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study

Year: 2019

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.09.021

Authors: R.S. Heist, J. Wolf, T. Seto, J.-Y. Han, N. Reguart, H.J.M. Groen, D.S.W. Tan, T. Hida, M.D. Jonge, S.V. Orlov, E.F. Smit, P.-J. Souquet, J. Vansteenkiste, M. Giovannini, S.L. Mouhaer, A. Robeva, M. Waldron-Lynch, E.B. Garon

Institutions: Massachusetts General Hospital, University Hospital Cologne, National Hospital Organization Kyushu Cancer Center, National Cancer Center, Hospital Clínic de Barcelona, University Medical Center Groningen, University of Groningen, National Cancer Centre Singapore, Aichi Cancer Center, Erasmus MC Cancer Institute, First Pavlov State Medical University of St. Petersburg, The Netherlands Cancer Institute, Hôpital Lyon Sud, Universitair Ziekenhuis Leuven, Novartis (United States), Novartis (France), Novartis (Switzerland), University of California, Los Angeles

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2982494888

FWCI: 0.824

Cites:

Cited by: 5

Related to: 10